Monthly Archives: October 2021

Cell Biology

Mantarray: Scalable Human-relevant 3D Engineered Cardiac and Skeletal Muscle Tissues for Therapeutics Discovery Upcoming Webinar Hosted by Xtalks -…

Learn how these advanced 3D tissue models generated on the Mantarray platform can improve the physiological relevance of preclinical cardiac and skeletal muscle models, accelerating the discovery of new medicines.

TORONTO (PRWEB) October 05, 2021

3D cellular models and organs-on-chips are poised to add tremendous value by providing human data earlier in the drug discovery pipeline. There is intense interest in adopting these 3D models in preclinical and translational research, but their complex implementation has remained a roadblock for many labs.

In this webinar, Curi Bio will present its Mantarray platform, which represents an easy-to-use, flexible, and scalable system for generating 3D EMTs at high-throughput with the ability to measure contractility in parallel. The platform features a novel method of casting 3D tissues that can be easily performed by nearly any cell biology researcher and can be readily adapted to a variety of cell lines and extracellular matrices. In addition, Mantarrays novel magnetic sensing modality permits contractility measurement of 24 tissues in parallel and in real time, while the cloud data analysis portal takes the guesswork out of analyzing and comparing results across experiments.

Register for this webinar to hear an overview of the technology, along with application examples across various use cases, including:

Learn how these advanced 3D tissue models generated on the Mantarray platform can improve the physiological relevance of preclinical cardiac and skeletal muscle models, accelerating the discovery of new medicines.

Join Dr. Nicholas Geisse, Chief Science Officer at Curi Bio, for the live webinar on Friday, October 22, 2021 at 1pm EDT.

For more information, or to register for this event, visit Mantarray: Scalable Human-Relevant 3D-Engineered Cardiac and Skeletal Muscle Tissues for Safety and Efficacy Studies.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.comFor information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Read the rest here:
Mantarray: Scalable Human-relevant 3D Engineered Cardiac and Skeletal Muscle Tissues for Therapeutics Discovery Upcoming Webinar Hosted by Xtalks -...

Cell Biology

Study reveals the underlying mechanisms behind obesity and type 2 diabetes link – News-Medical.Net

It is well known that obesity affects the body's insulin production and over time risks leading to type 2 diabetes and several other metabolic diseases. Now researchers at Karolinska Institutet in Sweden have found further explanation for why fat cells cause metabolic morbidity. The study, published in Nature Medicine, may have an impact on the treatment of comorbidity in obesity with already available drugs.

Obesity is a rapidly growing global public health problem, not least among children and young people. Many metabolic diseases, among them type 2 diabetes, are strongly associated with obesity. In order to reverse the trend, more knowledge is needed, among other things, about how fat cells (adipocytes) contribute to various harmful processes in tissues and organs.

When fat cells are enlarged, they begin to secrete factors that cause inflammation of the adipose tissue. Fat cell enlargement is also associated with insulin resistance, when cells in the body do not respond to insulin as they should. The important task of insulin is to regulate energy, glucose, for the body's cells. When that function is disturbed, as with insulin resistance, the risk of type 2 diabetes increases.

This relationship is well documented, but there has been a lack of knowledge about the underlying mechanisms behind enlarged fat cells (fat cell hypertrophy) and the secretion of pro-inflammatory substances.

Now researchers at Karolinska Institutet have shown that in obesity and insulin resistance, the cell activity of fat cells changes. As fat cells increase in cell size, nuclear size and nuclear DNA content also increases.

The process of cells not dividing but increasing in DNA content and cell size (endoreplication) is common among plants and animals. In contrast, the process has not been described for human fat cells (adipocytes), which can increase in size more than 200 times over their lifespan."

Qian Li, Researcher, Department of Cell and Molecular Biology, Karolinska Institutet, and Joint First Author

The natural process of fat cells increasing in size has several negative effects on health. The authors demonstrate that elevated levels of insulin in the blood cause premature aging, senescence, in some cells in the adipose tissue.

"Our results show that senescent fat cells increase the secretion of pro-inflammatory factors, and drive inflammation and pathology in human adipose tissue. This in turn affects the health of the whole body," says Carolina Hagberg, researcher at the Department of Medicine, Solna at Karolinska Institutet, and joint first author.

The results are based on analysis of adipose tissue from 63 people with BMI under 30 who underwent umbilical hernia surgery or cholecysectomy for gallstone disease, as well as 196 people with BMI over 30 who underwent bariatric surgery for obesity in Stockholm.

Using a commonly prescribed drug for type 2 diabetes, the researchers were able to block the formation of senescent fat cells and reduce the secretion of fat cell-based pro-inflammatory factors.

"These studies identify an unappreciated aspect of human adipocyte biology, the activation of a cell cycle program in obesity and hyperinsulinemia, which could pave the way for novel treatment strategies for obesity and associated co-morbidities, such as type 2 diabetes," says Kirsty Spalding, researcher at the Department of Cell and Molecular Biology, Karolinska Institutet, and the study's last author.

Source:

Journal reference:

Li, Q., et al. (2021) Obesity and hyperinsulinemia drive adipocytes to activate a cell cycle program and senesce. Nature Medicine. doi.org/10.1038/s41591-021-01501-8.

See original here:
Study reveals the underlying mechanisms behind obesity and type 2 diabetes link - News-Medical.Net

Cell Biology

Gene Identified in Mice and Monkeys Acts as Natural Antiviral Against HIV, Ebola, and Other Deadly Infections – Genetic Engineering &…

A research team led by scientists at the University of Utah (U of U) Health and the Rockefeller University has determined how a genetic mutation found in mice and in some New World monkeys interferes with how viruses such as HIV and Ebola infect cells. The gene, called RetroCHMP3, encodes an altered protein that disrupts the ability of certain viruses to exit an infected cell, and so prevents it from going on to infect other cells. The researchers suggest that the finding could help inform the future development of strategies for human therapeutics.

This was an unexpected discovery, said Nels Elde, PhD, senior author of the study and an evolutionary geneticist in the department of human genetics at U of U Health. We were surprised that slowing down our cell biology just a little bit throws virus replication off its game.

The team reported its findings in Cell, in a paper titled, RetroCHMP3 blocks budding of enveloped viruses without blocking cytokinesis.

In humans and other animals, a protein called charged multivesicular body protein 3, or CHMP3, is well known for playing a key part in cellular mechanisms that are vital for maintaining cellular membrane integrity, intercellular signaling, and cell division. The endosomal sorting complexes required for transport (ESCRT) pathway mediates essential cellular membrane fission events such as multivesicular body formation, cytokinetic abscission, and resealing of the post-mitotic nuclear envelope, the authors explained. Some viruses, including HIV, which are known as enveloped viruses, hijack this ESCRT pathway to exit infected cells, which they do by encasing themselves in the cell membrane and then budding off from the host cell.

The new study has found that the variant version of CHMP3, known as RetroCHMP3, which is found in monkeys and mice, delays that process long enough that the virus can no longer escape. RetroCHMP3 originated as a duplicated copy of CHMP3. So while humans only have the original CHMP3, species such as monkeys, mice, and other animals, have retroCHMP3 or other variants.

Based on their research, Elde and his colleagues suspected that the duplications of CHMP3 that they discovered in primates and mice blocked the ability of enveloped viruses to co-opt the ESCRT pathway into their escape mechanism, as protection against viruses like HIV and other viral diseases.

Building on their hypothesis, Elde and other scientists began exploring whether variants of CHMP3 might work as an antiviral. In laboratory experiments conducted elsewhere, a shorter, altered version of human CHMP3 successfully prevented HIV from budding off cells. There was, however, a glitch: the modified protein also disrupted important cellular functions, causing the cells to die.

Unlike other researchers, Elde and his colleagues at U of U Health had naturally occurring variants of CHMP3 from other animals available. So, working in collaboration with Sanford Simon, PhD, co-author and professor of cellular biophysics at the Rockefeller University, along with Phuong Tieu Schmitt, PharmD, research associate and Anthony Schmitt, PhD, professor of molecular virology, both at Pennsylvania State University, they tried a different approach.

Using genetic tools, they coaxed human cells to produce the version of retroCHMP3 found in squirrel monkeys. When they then infected the cells with HIV, they found that the virus had difficulty budding off from the cells, essentially stopping them in their tracks. When expressed in human cells, these retroCHMP3 proteins potently inhibit the release of retroviruses, paramyxoviruses, and filoviruses, the investigators wrote. And this occurred without disrupting metabolic signaling or related cellular functions that can cause cell death. Remarkably, retroCHMP3 proteins have evolved to reduce interactions with other ESCRT-III factors and have little effect on cellular ESCRT processes, revealing routes for decoupling cellular ESCRT functions from viral exploitation, the team noted.

The scientists also suggested that an antiviral approach based on exploiting retroCHMP may prove more durable than existing antiviral strategies. Additionally,the observation that retroCHMP3 alters ESCRT pathway function instead of targeting a viral protein raises theintriguing possibility that retroCHMP3 may be more resistant to viral counter-adaptations than other antiviral proteins that directly inhibit viral replication, they stated.

Were excited about the work because we showed some time ago that many different enveloped viruses use this pathway, called the ESCRT pathway, to escape cells, said Wes Sundquist, PhD, co-corresponding author of the study and chair of the department of biochemistry at the University of Utah. We always thought that this might be a point at which cells could defend themselves against such viruses, but we didnt see how that could happen without interfering with other very important cellular functions.

From an evolutionary perspective, Elde believes this represents a new type of immunity that can arise quickly to protect against short-lived threats. We thought the ESCRT pathway was an Achilles heel that viruses like HIV and Ebola could always exploit as they bud off and infect new cells, Elde said. RetroCHMP3 flipped the script, making the viruses vulnerable. Moving forward, we hope to learn from this lesson and use it to counter viral diseases.

More specifically, that lesson raises the possibility that an intervention that slows down the process may be inconsequential for the host, but provide us with a new anti-retroviral, added Simon.

View post:
Gene Identified in Mice and Monkeys Acts as Natural Antiviral Against HIV, Ebola, and Other Deadly Infections - Genetic Engineering &...

Cell Biology

Aging-US: Cellular senescence in lymphoid organs and immunosenescence – EurekAlert

image:With advancing age, the stromal cells in the lining of sinuses, that demarcate follicular zone from the marginal zone, become less organized accompanied with an altered localization of various cell types. The inflammatory environment created by the accumulation of SnCs impairs the functionality of several cells residing in the spleen. This functional impairment mediated improper antigen presenting capabilities lead to the establishment of an inadequate T-cell response against pathogenic invasion. Abbreviations: SnC: Senescent cell; SASP: Senescence associated secretory phenotype; ROS: Reactive Oxygen Species. view more

Credit: Correspondence to: Daohong Zhou email: zhoudaohong@cop.ufl.edu

Aging-USpublished "Cellular senescence in lymphoid organs and immunosenescence" which reported that immunosenescence is a multi-faceted phenomenon at the root of age-associated immune dysfunction.

Though both cellular senescence and immunosenescence have been studied extensively and implicated in various pathologies, their relationship has not been greatly explored. In the wake of an ongoing pandemic that disproportionately affects the elderly, immunosenescence as a function of age has become a topic of great importance.

The goal of this review is to explore the role of cellular senescence in age-associated lymphoid organ dysfunction and immunosenescence, and provide a framework to explore therapies to rejuvenate the aged immune system.

Dr. Daohong Zhou fromThe University of Floridasaid, "Aging is the gradual process of organismal deterioration which is associated with a multitude of age-related disorders and diseases that make one wonder if aging itself is a disease that needs to be addressed."

A shadow is cast on the benefits of longevity if the elderly are faced with the possibility of a decline in their quality of life. The world currently has over 700 million people who are over the age of 65, a number that is projected to grow rapidly in the near future. As advancing age is strongly correlated to decreased quality of life and increased risk of several age-related diseases, these demographics seem more dismal in prospering countries, with the USA and the UK having about 1618% of their population over the age of 65.

The silver lining to this otherwise tragic situation is that results from recent studies indicate that the aging process and the pace of organismal deterioration is malleable and can be influenced greatly by physiological, genetic, dietary and pharmaceutical interventions.

The Zhou Research Team concluded in theirAging-US Research Output, "The increasing array of genetic models of SnC clearance along with a growing panel of senolytic and senostatic agents, provide a unique opportunity for scientists to answer these questions to lay a strong foundation to this new avenue of research in immunosenescence. Ultimately, gaining a deeper understanding of the interaction between cellular senescence and immunosenescence will help in the development of improved therapeutics that will aid in the conservation of our vitality as we age."

Full Text -https://www.aging-us.com/article/203405/text

Correspondence to: Daohong Zhouemail:zhoudaohong@cop.ufl.edu

Keywords:cellular senescence,immunosenescence,immune senescence,senescence associated secretory phenotype (SASP),thymus

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research as well as topics beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, cancer, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR among others), and approaches to modulating these signaling pathways.

To learn more about Aging-US, please visithttp://www.Aging-US.comor connect with@AgingJrnl

Aging-US is published byImpact Journals, LLCplease visithttp://www.ImpactJournals.comor connect with@ImpactJrnls

Media Contact18009220957x105MEDIA@IMPACTJOURNALS.COM

Cellular senescence in lymphoid organs and immunosenescence

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Here is the original post:
Aging-US: Cellular senescence in lymphoid organs and immunosenescence - EurekAlert

Cell Biology

Study: Gene therapy can restore vision after stroke – EurekAlert

Key research finding

Most strokes happen when an artery in the brain becomes blocked. Blood flow to the neural tissue stops, and those tissues typically die. Because of the locations of the major arteries in the brain, many strokes affect motor function. Some affect vision, however, causing patients to lose their vision or find it compromised or diminished. A research team led by Purdue Universitys Alexander Chubykin, an associate professor of biological sciences in the College of Science, in collaboration with the team led by Gong Chen at Jinan University, China, has discovered a way to use gene therapy to turn glial brain cells into neurons, restoring visual function and offering hope for a way to restore motor function.

Neurons dont regenerate. The brain can sometimes remap its neural pathways enough to restore some visual function after a stroke, but that process is slow, its inefficient, and for some patients, it never happens at all. Stem cell therapy, which can help, relies on finding an immune match and is cumbersome and difficult. This new gene therapy, as demonstrated in a mouse model, is more efficient and much more promising.

We are directly reprogramming the local glial cells into neurons, Chubykin said. We dont have to implant new cells, so theres no immunogenic rejection. This process is easier to do than stem cell therapy, and theres less damage to the brain. We are helping the brain heal itself. We can see the connections between the old neurons and the newly reprogrammed neurons get reestablished. We can watch the mice get their vision back.

Chubykins research is especially important because visual function is easier than motor skills to measure accurately, using techniques including optical imaging in live mice to track the development and maturation of the newly converted neurons over the course of weeks. Perfecting and understanding this technique could lead to a similar technique reestablishing motor function. This research bridges the gap in understanding between the basic interpretation of the neurons and the function of the organs.

Purdue professors expertise

Chubykin is an expert in how neurons respond to visual experiences, as well as conditions including autism and ischemic stroke. He is affiliated with the Purdue Institute for Integrative Neuroscience and the Purdue Autism Research Center.

###

Journal name

Frontiers in Cell and Developmental Biology. The article is available online.

Funding

National Institute of Mental Health grant RF1 MH123401

Brief summary of methods

The team simulated an ischemic stroke affecting the visual centers in the brains of mice, mapping and measuring the extent of the neural and visual damage. Then, they used adeno-associated viruses to deliver NeuroD1 to glial cells in the affected part of the brain. They watched and measured as the glial cells were reprogrammed into neurons and were integrated into the visual cortex. After that, they measured the responses of these cells to visual stimulus and mapped the development of the visual cortex to measure the recovery of visual function.

Writer/Media contact: Brittany Steff, bsteff@purdue.edu

Source: Alexander Chubykin, chubykin@purdue.edu

Frontiers in Cell and Developmental Biology

Experimental study

Animals

Restoration of Visual Function and Cortical Connectivity After Ischemic Injury Through NeuroD1-Mediated Gene Therapy

18-Aug-2021

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Follow this link:
Study: Gene therapy can restore vision after stroke - EurekAlert

Cell Biology

NextCure Announces New Appointments to its Board of Directors – GlobeNewswire

BELTSVILLE, Md., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of Ellen G. Feigal, M.D., and Anne Borgman, M.D., to its Board of Directors.

I am thrilled to welcome two new members to NextCures Board of Directors, said Michael Richman, NextCures president and chief executive officer. Both Dr. Feigal and Dr. Borgman bring extensive experience in clinical and biopharmaceutical settings. Their insights will be valuable as NextCure continues to advance multiple clinical programs and investigate and develop new immunomedicines for cancer patients. These appointments follow the resignation of Stella Xu, Ph.D. from the board as previously announced. In addition, we would like to thank Stella Xu for her commitment and support in building NextCure.

Dr. Feigal is currently a Partner and Head of the Biologics Practice at NDA Partners LLC, a life sciences consulting and contract development organization, where she leads efforts in designing and executing product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology. Dr. Feigal is also adjunct faculty at the Sandra Day O'Connor College of Law, Arizona State University, where she teaches FDA drug law and medical research ethics and law. Her career includes over thirty years in clinical drug development, with roles spanning industry and academic medicine, including at the National Cancer Institute, where she served as Acting Director, Division of Cancer Treatment/Diagnosis during her tenure; Senior Vice President of Research and Development at the California Institute of Regenerative Medicine, and Executive Medical Director, global development at Amgen. She currently serves as a board member for Xencor. She earned her M.D. from the University of California, Davis, completed an internal medicine residency at Stanford University and a hematology/oncology fellowship at the University of California, San Francisco.

Dr. Borgman is currently Vice President and Global Therapeutic Area Lead, Hematology-Oncology, at Jazz Pharmaceuticals, where she is responsible for global development of the companys oncology and hematology drugs, including four marketed products. Previously, Dr. Borgman was Vice President, Clinical Research & Development, at Exelixis, where she was a Clinical Lead in the global development for cabozantinib in oncology indications including renal cell, hepatocellular and thyroid carcinoma. Earlier she was Chief Medical Officer and Vice President of Hana Biosciences (Talon Therapeutics), where she oversaw all aspects of the companys drug development operations. In addition, Dr. Borgman has worked as Associate Chief Medical Officer at KaloBios Pharmaceuticals, and she was formerly a Global Development Head at Abbott Pharmaceuticals (now AbbVie) where she was responsible for the early drug development of the PARP inhibitor, antimitotic, and Bcl-2/Bcl-XL platforms. Dr. Borgman continues clinical involvement, as a Consulting Associate Professor at Stanford University School of Medicines Stem Cell Transplant & Cell Biology program, and as a Clinical Associate at University of Chicagos Department of Pediatric Oncology and Stem Cell Research. Dr. Borgman completed her fellowship in pediatric hematology - oncology and stem cell transplant at UCLA David Geffen School of Medicine, trained in pediatrics at Texas Children's Hospital, Baylor College of Medicine, and earned her M.D. from Loyola University of Chicagos Stritch School of Medicine.

About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. http://www.nextcure.com

Cautionary Statement Regarding Forward-Looking StatementsStatements made in this press release that are not historical facts are forward-looking statements. Words such as expects, believes, intends, hope, forward and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCures plans, objectives and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCures actual results are described in NextCures filings with the Securities and Exchange Commission (the SEC), including NextCures most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

Investor InquiriesTimothy Mayer, Ph.D.NextCure, Inc.Chief Operating Officer(240) 762-6486IR@nextcure.com

Read the original post:
NextCure Announces New Appointments to its Board of Directors - GlobeNewswire

Cell Biology

Stunning Images Captured Using the Glowing Properties of Plant Cells – SciTechDaily

Formaldehyde fixation improves fluorescence patterns of tissues within maize (Zea mays) leaf cross sections. Treatment with a paraformaldehyde fixative solution revealed distinctive blue/green fluorescence of epidermis, trichomes, xylem, phloem, and bulliform cells resulting from aldehyde-induced fluorescence. By comparison, red autofluorescence of chlorophyll was observed in bundle sheath cells and mesophyll of leaf cross sections. This sample was prepared using a formaldehyde fixation and confocal imaging technique described by Pegg et al. in Algae to Angiosperms: Autofluorescence for rapid visualization of plant anatomy among diverse taxa in this issue. Formaldehyde fixation of Viridiplantae taxa samples such as Zea mays generates useful structural data while requiring no additional histological staining or clearing. In addition, image acquisition requires only minimal specialized equipment in the form of fluorescence-capable microscopes. Credit: Timothy J. Pegg

Scientists have come a long way since Antonie van Leeuwenhoek discovered teeming colonies of previously invisible bacteria and protozoa while peering through his custom-made microscopes. The architecture of cells, organelles, proteins, and even molecules has since been illuminated across the tree of life. Yet despite these advances, barriers still remain to comprehensively mapping the microscopic world. Before they can be viewed under a microscope, tissues and cell components must first be stained with dyes and fixatives and subjected to a lengthy preparation process.

In a new study published in the journal Applications in Plant Sciences, scientists obviate the need for specimen staining by tapping into the natural autofluorescence of tissues in species across the plant tree of life.

Our work provides a cost-effective, generalized protocol for plant sample preparation and visualization that is equally applicable to large research institutions and smaller plant science groups, said Dr. Timothy Pegg, a visiting assistant professor at Marietta College and lead author on the study.

When certain tissue types in both plants and animals absorb light, electrons in their atoms get a jolt of energy that bumps them into an excited state. In plant leaves, these electrons become so unstable that they break free from their atoms and are used by the plant to power photosynthesis. In other tissues, the excess energy is re-emitted in the form of low-frequency light bright enough to be detected with specialized microscopes.

Autofluorescence hasnt always been viewed as a good thing. In cases where researchers have to use stains to visualize specific structures, the light-emitting properties of nearby tissues can interfere by decreasing the contrast between different cell types.

But it can also be an indispensable resource for discovery. Autofluorescence has been used to detect early onset cancers, as well as other diseases and pathologies. Its been used to study how insects use their tongues and antennae to taste food, the mechanisms underlying tail regeneration in lizards, and to analyze the diversity of microscopic plankton in marine environments.

Autofluorescence is equally useful in plants, where it shows up in everything from the hard tissues that give woody plants their stability, to the water-wicking residue covering spores and pollen, to the diverse arsenal of toxic compounds plants produce to ward off would-be predators.

Up until now, however, researchers have lacked a one-size-fits-all protocol for detecting autofluorescent light in plants. The lack of a unified, standard approach is understandable, given there are nearly half-a-million living species of land plants and algae, but Pegg and his colleagues remained undeterred. They selected 12 species from several key plant groups separated by more than 500 million years of evolutionary history, including pines, bryophytes, flowering plants, and algae.

Using these representatives, they developed a cost-efficient method of tissue preservation without the need for stains or dyes.

While autofluorescence can often be directly visualized with confocal microscopes, it can also be induced or enhanced with different fixatives, including alcohols, ethanol, and compounds called aldehydes. Pegg and his colleagues chose five of the most effective among these to test their plant specimens. After marinating in fixative for 24 hours, the plants were rinsed, chopped to the width of a human hair, and mounted on a transparent slide for visualization.

When the researchers looked through the microscope, the miniature world of plant cells and organelles was brought into sharp focus. The rigid lines of cell walls stood out in bas-relief from the tightly packed chlorophyll inside. By honing in on particular wavelengths of light emitted by proteins, they could distinguish between the dense features of nuclei and the water- and sugar-conducting tissue snaking their way between cells.

Most fixatives performed well in the representative plants, with striking results, but algae proved to be an exception. Most land plants have thick, buttressing cell walls that help prevent water loss while providing structural support, qualities that algae lack. Due to their flimsier cellular scaffolding, ethanol and alcohol fixatives quickly penetrated the cell walls of algae and the sole liverwort (a plant closely related to mosses) used in the study, causing the organelles to wrinkle and deform. For these specimens, Pegg recommends sticking to aldehyde fixatives or reducing the amount of time used in the specimen preparation stages.

Most research labs also dont own the high-powered confocal microscopes required to view cellular structures at fine scales, instead paying hourly rates to use the equipment provided by their institution, an issue which Pegg and his colleagues hope their protocol can address.

Our simple sample preparation technique can cut down on the amount of time researchers need to spend visualizing samples on advanced microscopes, said Dr. Robert Baker, assistant professor of biology at Miami University and senior author on the study.

All of the chemicals and reagents used in the study are similarly inexpensive and readily available, meaning that just about anyone at a research institution can use this protocol to study subcellular interactions in plants.

Reference: Algae to angiosperms: Autofluorescence for rapid visualization of plant anatomy among diverse taxa by Timothy J. Pegg, Daniel K. Gladish and Robert L. Baker, 2 July 2021, Applications in Plant Sciences.DOI: 10.1002/aps3.11437

Read more:
Stunning Images Captured Using the Glowing Properties of Plant Cells - SciTechDaily

Immunology

Jennifer Anolik Named Interim Division Chief of Allergy, Immunology, and Rheumatology – URMC

Jennifer Anolik, M.D., Ph.D.

Jennifer Anolik, M.D., Ph.D., associate chair of research for the department of Medicine, has been named interim chief of the division of Allergy, Immunology & Rheumatology (AIR).

Anolik started at the University of Rochester as a student, earning her M.D. and Ph.D. in biochemistry as part of the Medical Scientist Training Program. She completed her residency in internal medicine followed by fellowship in rheumatology at URMC. Believing that there isnt a better place than the Medical Center, she stayed on as faculty for the last 20 years, bringing her total time with the University to 33 years.

Dr. Anolik has demonstrated excellence across each of our core missions and is an ideal choice for interim chief, said Ruth ORegan, M.D., chair of the Department of Medicine. Im excited to see her take the reins of the AIR division. I know shell be an outstanding leader.

Anolik succeeds Christopher Ritchlin, M.D., M.P.H., who has been with the University since 1991 as a faculty member, and spent the last eight years as division chief. As he steps down, Ritchlin will remain with the University to focus on teaching and research, with a concentration on psoriatic arthritis. During his tenure as chief, the AIR division has grown in both size and research funding. He was recently honored with a Lifetime Achievement Award from the National Psoriasis Foundation.

Anolik has an active research program with a focus on human B cell biology and underlying pathogenic mechanisms of rheumatologic conditions including rheumatoid arthritis and lupus. She is a member of the American Society of Clinical Investigation, has been continually NIH funded throughout her career, and is PI of the Accelerating Medicines Partnership (AMP) Network, focused on developing precision medicine approaches to the treatment of autoimmune disease. On the clinical side, Anolik focuses on lupus and is committed to translating state-of-the-art advances to her patients, as exemplified by her organization of a yearly patient Lupus Education Day for the past 15 years.

One of Anoliks passions is teaching and mentorship. She is the program director of the Physician Scientist Training Program, which offers career development to physician scientists. This ties in with her goals for the AIR division: to support faculty so they can be successful, and to bring diversity and equity to different areas of research. By providing stellar mentorship to students, residents and fellows, Anolik hopes that they will stay on to become faculty as she did.

Anolik also created the K Club, where trainees and junior faculty can present their NIH grant applications to senior faculty for input and feedback. The program is designed to increase their chances of successfully receiving funding.

We have a very talented faculty and division, said Anolik. My goal as chief is to make sure individuals are successful in their endeavors, and to bring even more collaboration to our clinical care and research by breaking down silos with other divisions and departments and finding common themes. Education and mentoring are a high priority of mine, because the future depends on who were training.

See the article here:
Jennifer Anolik Named Interim Division Chief of Allergy, Immunology, and Rheumatology - URMC

Immunology

The pathophysiology of sepsis-2021 update: Part 1, immunology and coagulopathy leading to endothelial injury – DocWire News

This article was originally published here

Am J Health Syst Pharm. 2021 Oct 4:zxab380. doi: 10.1093/ajhp/zxab380. Online ahead of print.

ABSTRACT

DISCLAIMER: In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

PURPOSE: To provide an overview of current literature on the pathophysiology of sepsis, with a focus on mediators of endothelial injury and organ dysfunction.

SUMMARY: Sepsis is a dysregulated response to infection that triggers cascades of interconnected systems. Sepsis has been a significant cause of mortality worldwide, and the recent viral pandemic that may produce severe sepsis and septic shock has been a major contributor to sepsis-related mortality. Understanding of the pathophysiology of sepsis has changed dramatically over the last several decades. Significant insight into the components of the inflammatory response that contribute to endothelial injury and trigger coagulation pathways has been achieved. Similarly, characterization of anti-inflammatory pathways that may lead to secondary infections and poor outcome has illustrated opportunities for improved therapies. Description of an increasing number of important mediators and pathways has occurred and may point the way to novel therapies to address immune dysregulation. Pharmacists will need a fundamental understanding of the overlapping pathways of the immune response to fully prepare for use of novel treatment options. While pharmacists typically understand coagulation cascade how to utilize anticoagulants, the issues in sepsis related coagulopathy and role of mediators such as cytokines and complement and role of activated platelets and neutrophils require a different perspective.

CONCLUSION: Pharmacists can benefit from understanding both the cellular and organ system issues in sepsis to facilitate assessment of potential therapies for risk and benefit.

PMID:34605875 | DOI:10.1093/ajhp/zxab380

See the article here:
The pathophysiology of sepsis-2021 update: Part 1, immunology and coagulopathy leading to endothelial injury - DocWire News

Immunology

Enlivex Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data … – The Baytown Sun

Country

United States of AmericaUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People's Socialist Republic ofAlgeria, People's Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60 deg S)Antigua and BarbudaArgentina, Argentine RepublicArmeniaArubaAustralia, Commonwealth ofAustria, Republic ofAzerbaijan, Republic ofBahrain, Kingdom ofBangladesh, People's Republic ofBarbadosBelarusBelgium, Kingdom ofBelizeBenin, People's Republic ofBermudaBhutan, Kingdom ofBolivia, Republic ofBosnia and HerzegovinaBotswana, Republic ofBouvet Island (Bouvetoya)Brazil, Federative Republic ofBritish Indian Ocean Territory (Chagos Archipelago)British Virgin IslandsBrunei DarussalamBulgaria, People's Republic ofBurkina FasoBurundi, Republic ofCambodia, Kingdom ofCameroon, United Republic ofCape Verde, Republic ofCayman IslandsCentral African RepublicChad, Republic ofChile, Republic ofChina, People's Republic ofChristmas IslandCocos (Keeling) IslandsColombia, Republic ofComoros, Union of theCongo, Democratic Republic ofCongo, People's Republic ofCook IslandsCosta Rica, Republic ofCote D'Ivoire, Ivory Coast, Republic of theCyprus, Republic ofCzech RepublicDenmark, Kingdom ofDjibouti, Republic ofDominica, Commonwealth ofEcuador, Republic ofEgypt, Arab Republic ofEl Salvador, Republic ofEquatorial Guinea, Republic ofEritreaEstoniaEthiopiaFaeroe IslandsFalkland Islands (Malvinas)Fiji, Republic of the Fiji IslandsFinland, Republic ofFrance, French RepublicFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabon, Gabonese RepublicGambia, Republic of theGeorgiaGermanyGhana, Republic ofGibraltarGreece, Hellenic RepublicGreenlandGrenadaGuadaloupeGuamGuatemala, Republic ofGuinea, RevolutionaryPeople's Rep'c ofGuinea-Bissau, Republic ofGuyana, Republic ofHeard and McDonald IslandsHoly See (Vatican City State)Honduras, Republic ofHong Kong, Special Administrative Region of ChinaHrvatska (Croatia)Hungary, Hungarian People's RepublicIceland, Republic ofIndia, Republic ofIndonesia, Republic ofIran, Islamic Republic ofIraq, Republic ofIrelandIsrael, State ofItaly, Italian RepublicJapanJordan, Hashemite Kingdom ofKazakhstan, Republic ofKenya, Republic ofKiribati, Republic ofKorea, Democratic People's Republic ofKorea, Republic ofKuwait, State ofKyrgyz RepublicLao People's Democratic RepublicLatviaLebanon, Lebanese RepublicLesotho, Kingdom ofLiberia, Republic ofLibyan Arab JamahiriyaLiechtenstein, Principality ofLithuaniaLuxembourg, Grand Duchy ofMacao, Special Administrative Region of ChinaMacedonia, the former Yugoslav Republic ofMadagascar, Republic ofMalawi, Republic ofMalaysiaMaldives, Republic ofMali, Republic ofMalta, Republic ofMarshall IslandsMartiniqueMauritania, Islamic Republic ofMauritiusMayotteMicronesia, Federated States ofMoldova, Republic ofMonaco, Principality ofMongolia, Mongolian People's RepublicMontserratMorocco, Kingdom ofMozambique, People's Republic ofMyanmarNamibiaNauru, Republic ofNepal, Kingdom ofNetherlands AntillesNetherlands, Kingdom of theNew CaledoniaNew ZealandNicaragua, Republic ofNiger, Republic of theNigeria, Federal Republic ofNiue, Republic ofNorfolk IslandNorthern Mariana IslandsNorway, Kingdom ofOman, Sultanate ofPakistan, Islamic Republic ofPalauPalestinian Territory, OccupiedPanama, Republic ofPapua New GuineaParaguay, Republic ofPeru, Republic ofPhilippines, Republic of thePitcairn IslandPoland, Polish People's RepublicPortugal, Portuguese RepublicPuerto RicoQatar, State ofReunionRomania, Socialist Republic ofRussian FederationRwanda, Rwandese RepublicSamoa, Independent State ofSan Marino, Republic ofSao Tome and Principe, Democratic Republic ofSaudi Arabia, Kingdom ofSenegal, Republic ofSerbia and MontenegroSeychelles, Republic ofSierra Leone, Republic ofSingapore, Republic ofSlovakia (Slovak Republic)SloveniaSolomon IslandsSomalia, Somali RepublicSouth Africa, Republic ofSouth Georgia and the South Sandwich IslandsSpain, Spanish StateSri Lanka, Democratic Socialist Republic ofSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudan, Democratic Republic of theSuriname, Republic ofSvalbard & Jan Mayen IslandsSwaziland, Kingdom ofSweden, Kingdom ofSwitzerland, Swiss ConfederationSyrian Arab RepublicTaiwan, Province of ChinaTajikistanTanzania, United Republic ofThailand, Kingdom ofTimor-Leste, Democratic Republic ofTogo, Togolese RepublicTokelau (Tokelau Islands)Tonga, Kingdom ofTrinidad and Tobago, Republic ofTunisia, Republic ofTurkey, Republic ofTurkmenistanTurks and Caicos IslandsTuvaluUganda, Republic ofUkraineUnited Arab EmiratesUnited Kingdom of Great Britain & N. IrelandUruguay, Eastern Republic ofUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet Nam, Socialist Republic ofWallis and Futuna IslandsWestern SaharaYemenZambia, Republic ofZimbabwe

See the original post here:
Enlivex Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data ... - The Baytown Sun